A Phase III randomized trial published in JAMA Network Open found no significant difference in symptom improvement between ...

One’s about behaviour, the other about emotions. Here’s how to respond to tantrums and meltdowns without losing your cool.

An AI tool showed noninferiority to senior endocrinology physicians in insulin titration for hospitalized patients with type ...

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...

The biosimilar SYSA1902 is similar to reference ustekinumab for both efficacy and safety measures among patients with plaque psoriasis.

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have ...

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for ...

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

Nanobiotix announces full results from completed phase 1 study evaluating JNJ-1900 (NBTXR3) in pancreatic cancer: Paris Tuesday, May 6, 2025, 11:00 Hrs [IST] Nanobiotix, a late-st ...